A&G Pharmaceutical, Inc.
A&G Pharmaceutical
is a privately held theranostics company focused on the rapid development
of monoclonal antibodies to disease-specific antigens as a basis for novel
therapeutic and diagnostic products addressing a broad range of diseases.
Precision Antibody Services:
A&G's PRECISION ANTIBODY™ service rapidly develops customized, high-affinity monoclonal antibodies to your target antigen in 40 DAYS. More >
Request a Quote by filling out our simple online form.
Breast Cancer Diagnostic Kits:
A&G is developing a line of diagnostic test kits that will dramatically improve early detection, diagnosis, and treatment of breast cancer by detecting a new cancer biomarker known as GP88. More >
News:
December 14, 2007-A&G Pharmaceutical Receives $870,000 Grant from Avon Foundation to Advance Innovative Blood Diagnostic Test for Early Detection of Breast Cancer. Press Release
August 31, 2007 - A&G Pharmaceutical, Inc. announced that it has received an equity investment from Olympus Corporation. Press Release
Dec 15, 2006 - A&G presented at the San Antonio Breast Cancer Symposium at a general session titled "PC-cell derived growth factor (PCDGF/GP88, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells."
October 1, 2006 - A&G featured in Genetic Engineering New's article titled "Bringing Pharmacogenomics into the Clinic" by Catherine Shaffer. Full Article
June 7, 2006 - A&G Pharmaceutical and Celltrion Announce Bioprocess Development & Manufacturing Agreement for A&G Anti-GP88 Cancer Therapeutic Antibody — Deal worth up to $8.4 million plus royalties includes $2 million equity investment in A&G.
February 21, 2006 - A&G awarded the Enterpreneurial Spirit Award at the Greater Baltimore Councils Bioscience Awards.
February 17, 2006 - Article on Fox News, Health Section "Maryland Company Developing New Breast Cancer Test Kit" by Elissa Petruzzi
For more articles, press releases, and highlights. More >